Pharnext PLEO-CMT-FU Phase 3 Open Label Extension Study Call Transcript
Welcome to the Pharnext conference call. This call is being webcast live on Pharnext website at pharnext.com. Please be advised that this call is being recorded at the company's request. This call is the property of Pharnext SA and recording, reproduction or transmission of this call without the expressed written consent of Pharnext SA is strictly prohibited.
At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions.
I would now like to introduce, Peter Collum, Chief Financial Officer and Chief Business Officer at Pharnext.
Thank you. Hello, everyone and thank you for joining and welcome to Pharnext Conference Call to discuss data from our Phase 3 Open-Label Extension Study of PXT3003 in patients with Charcot-Marie-Tooth Type 1A disease.
With me on today's call is Professor Daniel Cohen, Co-founder and Chief Executive Officer along with other members of management as well as four eminent scientists in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
